Ocuphire Pharma
product candidate profile efficacy data safety data near visual acuity light dark redness | Ocuphire Pharma
Company
Deck Type
Deck date
March 2021
Slide
22 of 29
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2022
product candidate profile on | Ocuphire Pharma
Investor Day
January 2022
product candidate profile on | Ocuphire Pharma
Related slides by other companies
Alkermes
Investor Day
March 2021
advancing across key domains submission of data for presentation at upcoming congresses artistry updated safety and efficacy data artistry dose and initial efficacy and safety data advance ongoing studies advance interactions with regulatory authorities initiate studies in mucosal melanoma and platinum resistant ovarian cancer to support potential registration pursue strategic collaborations to expand development program | Alkermes
MAIA Biotechnology
Investor Presentation
November 2023
thio trial planned a | MAIA Biotechnology
Bill.com
Investor Presentation
August 2023
expanding network effects | Bill.com
Kymera
Results
December 2022
interim safety data summary | Kymera
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights